The combination of KRAS inhibitors with downstream pathway inhibitors is less commonly reported, and the combined targeting of the MAPK-ERK and PI3K-AKT-mTOR pathways was ineffective in pancreatic cancer models. This evidence concerns the gene KRAS and familial pancreatic carcinoma.